We are a neuroimaging-focused CRO with a strong track record of delivering top quality results in early and late phase clinical trials across a range of diseases
Our multidisciplinary team provides the full spectrum of Imaging CRO services, including imaging study operations, central eligibility & safety reads, and quantitative image processing & analysis
Imaging Study Operations
We provide end-to-end Imaging Core Lab services for small to large scale clinical trials. Our services are designed to facilitate acquisition of the highest quality imaging data.
Our Imaging Study Operations services include imaging site qualification, image acquisition protocol design, imaging site training, in-study site support, image transfer & reconciliation, image quality control (QC) review, study analytics (KPIs), and project management. Our Imaging Operations Management Platform is a state-of-the-art technology that allows our expert team to efficiently and effectively manage all aspects of the imaging study.
Eligibility & Safety Reads
We have a global network of board-certified neuroradiologists and nuclear medicine physicians that can perform central eligibility and safety reads of MRI (including ARIA-E and ARIA-H), PET (including Amyloid, Tau, FDG), and SPECT (including DaTscan) scans for clinical trials using our web-based image review platform.
We have strong expertise in designing the image review criteria and process, as well as writing and implementing Image Review Charters. We generate read reports and closely monitor KPIs (including turnaround times) associated with the review process.
Image Processing & Analysis
We have developed the most advanced technologies for processing and analysis of neuroimaging data in the industry. Our 21 CFR Part 11 compliant, validated software platform is purpose-built for clinical trials. Our expert team of imaging scientists and software developers leverage cutting-edge methods, including machine learning and deep learning algorithms, for robust fully-automated image processing & analysis of MRI, PET, and SPECT data.
Careful attention to processed image quality is paramount to the success of an imaging study and an integral part of the Biospective process. We have extensive experience with quantitative imaging biomarkers for a range of neurological diseases, including Alzheimer's disease, ALS, Parkinson's disease, Multiple System Atrophy, Multiple Sclerosis, as well as MPS and other rare, genetic diseases.
Our Latest Innovations
Narrated presentations of our scientific advancements
Reduction of brain glucose metabolism in MCI is primarily driven by tau pathology
By applying a singular value decomposition (SVD) analysis to tau, amyloid, and FDG PET images from MCI subjects in the ADNI study, we demonstrate a more significant role of tau than β-amyloid in the reduction of cerebral glucose metabolism.
Spatial association between distributed β-amyloid and tau varies with cognition
Through the use of a novel computational approach that accounts for both linear and nonlinear relationships, we have found that β-amyloid and tau act in a spatially coordinated manner that depends on the cognitive stage of Alzheimer's disease.
A novel computational method for harmonization of brain PET image spatial resolution without phantoms
Learn about Biospective’s SPITFIRE method, a new algorithm for harmonizing the spatial resolution of positron emission tomography (PET) images in multicenter clinical trials without the need for phantoms.
Scientific Resources
Up-to-date information on topics and best practices related to the use of medical imaging in clinical trials of neurological diseases.
